Strong Revenue Growth
Pulmonx reported worldwide sales of $23.8 million in Q4 2024, reflecting 23% growth over the same period last year. Full year 2024 worldwide revenue was $83.8 million, representing 22% growth over 2023.
Record International Sales
Record international sales of $7.9 million in Q4 2024, representing 42% growth year-over-year. Strong performance in key European markets and successful expansion in China.
Expansion of U.S. Account Base
Expanded U.S. account base with 52 new centers in 2024, ending the year with 283 active accounts in Q4.
Notable Clinical Trials and Studies
Launched AeriSeal CONVERT II Pivotal Trial and Japanese post-market study. Demonstrated successful conversion of collateral ventilation status in 77.6% of patients in AeriSeal CONVERT Trial.
Innovation and Product Launches
Introduced LungTrax platform and new Chartis Precision Catheter. Launched first U.S. TV commercial reaching over 11 million people.
Positive Financial Metrics
Gross margin for fiscal year 2024 was 74%, consistent with 2023. Adjusted EBITDA loss improved by 10% in Q4 2024 and by 20% for the full year.